Home > A. Molecular pathology > Targeted therapy > Small molecules > afatinib

afatinib

Tuesday 10 June 2014

WKP

Afatinib (INN; trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok) is an angiokinase inhibitor approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim.

It acts as an angiokinase inhibitor.